Losses increase slightly at drug firm BioCryst
Durham, N.C. —
A year ago, BioCryst reported a loss of $10.6 million.
The company reported its financials before the markets opened Thursday.
BioCryst revenues increased to $12 million from $10.5 million a year ago, driven primarily by its contract with the U.S. Department of Health and Human Services to develop the flu treatment Peramivir.
Research and development costs climbed $1 million to $19.2 million and general expenses increased $700,000 to $3.8 million, the company said.
BioCryst employs some 50 people with 30 located at its Durham research and development operation.
For the financial report, read here.
Get the latest news alerts: Follow LTW at Twitter.
Please Log In to add a comment.
Best of TechWire Insider
- Star Trek gets real: Durham startup delivers interactive holograms
- Every tech company needs to join 'Global Government Surveillance Reform' movement
- Durham entrepreneurs find ally in Charlotte medtech incubator
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution